Patents by Inventor Peter Fitzgerald

Peter Fitzgerald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150346227
    Abstract: An immunoassay method for detecting and determining adamantane substituted indazole and indole synthetic cannabinoids is described. Also described are components for use in implementing the method, namely, antibodies, detection agents, solid state devices and kits as well as immunogens used to raise the antibodies.
    Type: Application
    Filed: May 28, 2015
    Publication date: December 3, 2015
    Inventors: Ivan McConnell, Elouard Benchikh, Philip Lowry, Peter Fitzgerald
  • Patent number: 9162853
    Abstract: An assembly for monitoring load on a drum during an operation in a well with a well access line deployed from the drum. The assembly may include multiple line detection mechanisms for acquiring real-time information relative to dynamic characteristics of the lone over the course of the operation. The assembly also includes a processor for computing the real-time information in light of pre-stored information relative to physical characteristics of the line and the drum. As a result, real-time monitoring of a load on the drum may be achieved. Thus, the operation may be adjusted in real-time as necessary to avoid over-loading of the drum. Additionally, a drum load history may be recorded so as to better account for the true condition of the drum following successive operations.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: October 20, 2015
    Assignee: Schlumberger Technology Corporation
    Inventors: Sebastien Ives, Peter Fitzgerald
  • Publication number: 20150269311
    Abstract: The invention provides a method of defining the likelihood of a subject having bladder cancer, comprising the steps of: (A) assessing the subject's likelihood of having bladder cancer by: i. identifying at least one sub-population group appropriate to the subject; ii. determining the level of one or more biomarkers selected according to the sub-population group in a sample obtained from the subject; iii. inputting each of the biomarker values into an algorithm to produce an output value; and iv. correlating the output value with the likelihood of the subject having bladder cancer, wherein the sub-population group is selected according to smoking habits, gender, presence/absence of stone disease, history of benign prostate enlargement (BPE) or prescription of anti-hypertensive, anti-platelet and/or anti-ulcer medication, and (B) determining the subject's stratified risk level of serious disease by: v.
    Type: Application
    Filed: October 16, 2013
    Publication date: September 24, 2015
    Inventors: Mark William Ruddock, Cherith N. Reid, Kate E. Williamson, Frank Emmert-Streib, John V. Lamont, Peter Fitzgerald
  • Patent number: 9128108
    Abstract: The invention relates to an immunoassay method and kit for the detection and/or the determination of mephedrone, mephedrone metabolites and related compounds. The invention is underpinned by a novel antibody, derived from a novel immunogen, that is sensitive and binds to mephedrone, mephedrone metabolites and related compounds.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: September 8, 2015
    Assignee: Randox Laboratories Limted
    Inventors: Robert Ivan McConnell, Elouard Benchikh, Philip Andrew Lowry, Stephen Peter Fitzgerald
  • Publication number: 20150219670
    Abstract: The present invention provides a method of stratifying a patient suffering from CKD into one of stages 1-3 of CKD, comprising determining the level of the biomarkers FABP1, ?-GT, AST, creatinine and cystatin C in a sample obtained from the patient and comparing the level of FABP1 in the sample to a control value and the levels of ?-GT, AST, creatinine and cystatin C in the sample to a range of control values for each biomarker, wherein an increased level of FABP1 compared to the control value and levels of ?-GT, AST, creatinine and cystatin C within the range of control values for each biomarker indicate that the patient suffers from stage 1 CKD or wherein an increased level of FABP1 compared to the control value, levels of ?-GT and AST within the range of control values for each biomarker, and increased levels of creatinine and cystatin C compared to an upper threshold of the control range for these biomarkers indicate that the patient suffers from stage 2 or stage 3 CKD.
    Type: Application
    Filed: August 12, 2013
    Publication date: August 6, 2015
    Inventors: Ivan McConnell, Stephen Peter Fitzgerald, John Lamont, Claran Richardson
  • Patent number: 9079964
    Abstract: The invention relates to the detection and quantification of cyclopropylindole based synthetic cannabinoids UR-144 and XLR-11 by providing antibodies based on novel immunogens. These antibodies can be incorporated into methods and kits for the detection of UR-144, XLR-11 and their metabolites.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: July 14, 2015
    Assignee: RANDOX LABORATORIES LIMITED
    Inventors: Elouard Benchikh, Ivan McConnell, Philip Lowry, Peter Fitzgerald
  • Publication number: 20150126385
    Abstract: The present invention provides biomarker-based methods for diagnosing stroke in a patient suspected of having suffered a stroke, and also for discriminating between ischemic stroke and transient ischemic attack. Substrates comprising probes for specific combinations of biomarkers useful in the methods of the invention are also described.
    Type: Application
    Filed: December 3, 2012
    Publication date: May 7, 2015
    Applicant: RANDOX LABORATORIES LTD.
    Inventors: John Lamont, Ivan Mc Connell, Peter Fitzgerald
  • Publication number: 20150118763
    Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.
    Type: Application
    Filed: November 7, 2014
    Publication date: April 30, 2015
    Inventors: STEPHEN PETER FITZGERALD, PAUL JOHN INNOCENZI, IVAN ROBERT McCONNELL, PHILIP ANDREW LOWRY, ELOUARD BENCHIKH
  • Publication number: 20150038366
    Abstract: Immunoassay methods and their requisite components for the detection and determination of phenethylamines of the 2C and DO sub-families are described.
    Type: Application
    Filed: August 5, 2014
    Publication date: February 5, 2015
    Inventors: Elouard Benchikh, Peter Fitzgerald, Ivan McConnell, Philip Lowry
  • Patent number: 8906633
    Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: December 9, 2014
    Assignee: Randox Laboratories Limited
    Inventors: Elouard Benchikh, Stephen Peter Fitzgerald, Paul John Innocenzi, Philip Andrew Lowry, Ivan Robert McConnell
  • Publication number: 20140343601
    Abstract: Systems and methods for treating internal tissue defects, such as septal defects, with clip-based devices are provided. An exemplary clip-based device includes a tubular body having at least a first and a second deflectable member coupled thereto. The first and second members are coupled on opposite ends of the tubular body and configured to deflect between an undeployed configuration and a deployed configuration. In the deployed configuration, each member extends outwardly away from the tubular body in a position configured to abut a tissue surface. The first and second members are preferably configured to maintain a tissue wall therebetween and at least partially close any opening in the tissue wall.
    Type: Application
    Filed: April 7, 2014
    Publication date: November 20, 2014
    Applicant: PROMED, INC.
    Inventors: Ryan Abbott, W. Martin Belef, Dean Carson, Peter Fitzgerald, Ronald J. Jabba, James Nielson, Peter Thornton
  • Publication number: 20140336283
    Abstract: The invention describes epistatic interactions between single nucleotide polymorphisms on genes associated with blood pressure and provides an application for their use in a method to determine an individual's susceptibility to hypertension and hence whether anti-hypertensive treatment will be beneficial for said individual. In addition gene expression levels are also linked to blood pressure and may also be used to determine susceptibility to hypertension.
    Type: Application
    Filed: December 21, 2012
    Publication date: November 13, 2014
    Applicant: RANDOX LABORATORIES LTD.
    Inventors: Sophie Visvikis-Siest, Said El Shamieh, Helena Murray, John Lamont, Peter Fitzgerald
  • Patent number: 8852953
    Abstract: The invention relates to novel immunogens, antibodies, methods and kits for use in immunoassays to detect and quantify zaleplon, metabolites of zaleplon and indiplon. These are the first described immunoassays for these compounds and have greater sensitivity than alternative analytical techniques.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: October 7, 2014
    Assignee: Randox Laboratories Ltd.
    Inventors: Elouard Benchikh, Stephen Peter Fitzgerald, Philip Andrew Lowry, Ivan Robert McConnell
  • Publication number: 20140287441
    Abstract: The invention relates to the detection and quantification of cyclopropylindole based synthetic cannabinoids UR-144 and XLR-11 by providing antibodies based on novel immunogens. These antibodies can be incorporated into methods and kits for the detection of UR-144, XLR-11 and their metabolites.
    Type: Application
    Filed: October 30, 2013
    Publication date: September 25, 2014
    Applicant: Randox Laboratories Limited
    Inventors: Elouard Benchikh, Ivan McConnell, Philip Lowry, Peter Fitzgerald
  • Publication number: 20140242617
    Abstract: The invention relates to the field of drug detection and describes antibody-based components methods and kits for the detection and quantification of alkaloids of the plant kratom. The invention is underpinned by novel antibodies which specifically bind to mitragynine alkaloids found in the kratom plant and their metabolites.
    Type: Application
    Filed: February 19, 2014
    Publication date: August 28, 2014
    Applicant: Randox Laboratories Limited
    Inventors: Elouard Benchikh, Ivan McConnell, Philip Lowry, Peter Fitzgerald
  • Publication number: 20140242618
    Abstract: The invention provides novel antibodies which specifically bind to the methylphenidate metabolite, ritalinic acid, enabling an immunoassay that can detect methyphenidate in biological samples for an extended period following its ingestion. The invention also describes novel conjugates and kits incorporating the antibodies.
    Type: Application
    Filed: February 21, 2014
    Publication date: August 28, 2014
    Applicant: RANDOX LABORATORIES LIMITED
    Inventors: Philip Lowry, Elouard Benchikh, Ivan McConnell, Peter Fitzgerald
  • Publication number: 20140099651
    Abstract: The invention provides novel haptens and immunogens for the preparation of novel monoclonal antibodies, which detect the synthetic opioid meperidine and its active metabolite normeperidine. These antibodies enable methods and kits, which are useful in an immunoassay for therapeutic drug monitoring (TDM) and in extending the window of detection for cases of abuse and drug-facilitated sexual assault (DFSA).
    Type: Application
    Filed: October 8, 2013
    Publication date: April 10, 2014
    Inventors: Ivan McConnell, Elouard Benchikh, Philip Lowry, Peter Fitzgerald
  • Patent number: 8673652
    Abstract: The immunoassay method and kit are provided for the detection and/or the determination of zolpidem. The disclosure provides novel antibodies, derived from a novel immunogen, that are highly sensitive and bind to zolpidem and its main urinary metabolite [3-(2-N,N-dimethylamino-2-oxoethyl)-6-methylimidazo[1,2-a]pyridin-2-yl]benzoic acid, enabling an extension of the detection window of zolpidem in individuals who have abused the drug, or have been victim of its side-effects or its criminal misuse.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: March 18, 2014
    Assignee: Randox Laboratories Limited
    Inventors: Stephen Peter Fitzgerald, Robert Ivan McConnell, Philip Andrew Lowry, Elouard Benchikh
  • Publication number: 20140007676
    Abstract: A capacitive liquid level sensor is provided comprising a capacitive probe having a capacitance and comprising a sensing tip wherein the capacitive probe is configured such that the capacitance of the probe changes when the sensing tip is exposed to liquid. A signal generator operates to supply an electrical signal alternating between a high and low state to the capacitive probe, the electrical signal being configured such that the probe is alternately charged and discharged when the signal is high or low respectively. A comparator operates to detect the magnitude of an electrical signal across the capacitive probe and provides a first output signal value when the detected signal magnitude is greater than a predetermined threshold value and a second output signal value when the signal magnitude is less than the threshold value.
    Type: Application
    Filed: August 5, 2011
    Publication date: January 9, 2014
    Applicant: Randox Laboratories Ltd.
    Inventors: Ian Armstrong, Michael Duffy, Stephen Peter Fitzgerald
  • Publication number: 20140004623
    Abstract: The invention relates to the detection and quantification of 1-benzylpiperazine and its metabolites. The invention is underpinned by novel polyclonal antibodies with unique binding properties which enable immunoassay methods and kits for various applications.
    Type: Application
    Filed: July 1, 2013
    Publication date: January 2, 2014
    Inventors: Elouard BENCHIKH, Ivan McCONNELL, Philip LOWRY, Peter FITZGERALD